The Medical University of South Carolina (MUSC) was awarded a $792,245 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "LEVERAGING LINEAGE ADDICTION: NUCLEAR DELIVERY OF THERAPEUTIC TRANSGENES RESPONSIVE TO ONCOGENIC TRANSCRIPTION FACTOR OVEREXPRESSION," will fund research focused on developing innovative gene therapy approaches to treat various medical conditions. The award has a performance period of September 1, 2024 through August 31, 2027. The Military Medical Research and Development program supports a broad range of biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the general public. MUSC, as a leading academic health sciences center, has extensive expertise in areas such as cancer research, neuroscience, and substance use disorders, and will leverage this grant to advance its scientific capabilities and deliver new therapeutic solutions.